| Literature DB >> 31602170 |
Hua Zhang1, Xiang Lan1, Bing Peng2, Bo Li3.
Abstract
BACKGROUND: Laparoscopy has been widely used in general surgical procedures, but total laparoscopic pancreaticoduodenectomy (TLPD) is still a complex and challenging surgery that is only performed in a small number of patients at a few large academic medical centers. Although the safety and feasibility of TLPD have been established, few studies have compared it with open pancreaticoduodenectomy (OPD) with regard to perioperative and oncological outcomes. Therefore, we carried out a meta-analysis to evaluate whether TLPD is superior to OPD. AIM: To compare the treatment outcomes of TLPD and OPD in order to assess the safety and feasibility of TLPD.Entities:
Keywords: Feasibility; Meta-analysis; Open pancreaticoduodenectomy; Safety; Total laparoscopic pancreaticoduodenectomy
Mesh:
Year: 2019 PMID: 31602170 PMCID: PMC6785520 DOI: 10.3748/wjg.v25.i37.5711
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Figure 1The PRISMA flowchart of the literature review.
Characteristics of 28 included studies.
| Zimmerman | 2018 | USA | Retrospective analysis | 280 | 6336 | 78 (27.86) | NR | NR | NR | 7 |
| Tran | 2016 | USA | Retrospective analysis | 681 | 14893 | NR | NR | NR | NR | 7 |
| Tee | 2015 | USA | Retrospective analysis | 113 | 225 | NR | YES | YES | YES | 8 |
| Tan | 2015 | China | Retrospective analysis | 30 | 30 | NR | YES | YES | NR | 9 |
| Stauffer | 2017 | USA | Retrospective analysis | 58 | 193 | NR | YES | YES | YES | 8 |
| Song | 2015 | Korea | Matched case-control study | 97 | 198 | NR | YES | YES | YES | 8 |
| Sharpe | 2015 | USA | Retrospective analysis | 384 | 4037 | NR | NR | NR | NR | 7 |
| Senthilna-than | 2015 | India | Retrospective analysis | 45 | 118 | NR | NR | NR | NR | 8 |
| Poves | 2018 | Spain | RCT | 32 | 29 | 8 (25.00) | YES | YES | YES | 4 |
| Palanivelu | 2017 | India | RCT | 32 | 32 | 1 (3.13) | YES | YES | YES | 3 |
| Meng | 2018 | China | Retrospective analysis | 58 | 58 | NR | YES | YES | YES | 9 |
| Lee | 2018 | Korea | Matched case-control study | 31 | 31 | NR | NR | NR | NR | 9 |
| Khaled | 2018 | UK | Matched case-control study | 15 | 15 | 1 (6.67) | YES | YES | YES | 9 |
| Kantor | 2017 | USA | Retrospective analysis | 828 | 7385 | NR | NR | NR | NR | 7 |
| Hakeem | 2014 | UK | Matched case-control study | 12 | 12 | NR | NR | NR | YES | 9 |
| Gerber | 2017 | USA | Retrospective analysis | 52 | 50 | NR | NR | NR | NR | 8 |
| Dokmak | 2015 | France | Matched case-control study | 46 | 46 | 3 (6.52) | YES | YES | YES | 9 |
| Delitto | 2016 | USA | Retrospective analysis | 52 | 50 | NR | YES | YES | YES | 8 |
| Croome | 2014 | USA | Retrospective analysis | 108 | 214 | 7 (6.48) | YES | YES | YES | 8 |
| Conrad | 2017 | USA | Retrospective analysis | 40 | 25 | 9 (22.50) | YES | YES | YES | 8 |
| Chopinet | 2018 | France | Retrospective analysis | 65 | 290 | NR | YES | YES | YES | 8 |
| Chen | 2018 | China | Retrospective analysis | 47 | 55 | NR | YES | YES | YES | 8 |
| Chapman | 2018 | USA | Retrospective analysis | 22 | 25 | 0 (0) | YES | YES | YES | 8 |
| Chapman | 2018 | USA | Retrospective analysis | 248 | 1520 | 74 (29.84) | NR | NR | NR | 7 |
| Asbun | 2012 | USA | Retrospective analysis | 53 | 215 | 9 (15.00) | YES | YES | NR | 8 |
| Zureikat | 2011 | USA | Matched case-control study | 14 | 14 | 2 (14.29) | YES | NR | YES | 9 |
| Mesleh | 2013 | USA | Retrospective analysis | 75 | 48 | 10 (13.33) | YES | YES | YES | 8 |
| Speicher | 2014 | USA | Retrospective analysis | 25 | 84 | NR | YES | NR | NR | 8 |
Newcastle-Ottawa scale;
Jadad scale. TLPD: Total laparoscopic pancreaticoduodenectomy; OPD: Open pancreaticoduodenectomy; ISGPF: International Study Group of Pancreatic Fistula; ISGPS: International Study Group on Pancreatic Surgery; Clavien-Dindo: The Clavien-Dindo Classification of Surgical Complications; RCT: Randomized controlled trial; NR: Not reported.
Meta-analysis of intraoperative and perioperative results
| Operative time | 11 | 642 | 1129 | < 0.00001 | 99% | R | WMD = 77.92 | 40.89, 114.95 | < 0.0001 |
| EBL | 10 | 612 | 1324 | < 0.00001 | 98% | R | WMD = -260.08 | -336.02, -184.14 | < 0.00001 |
| Transfusion rate | 12 | 1254 | 15964 | 0.003 | 60% | R | OR = 0.51 | 0.36, 0.72 | 0.0001 |
| Overall morbidity | 12 | 1407 | 22126 | 0.10 | 37% | F | OR = 0.82 | 0.73, 0.92 | 0.0008 |
| Major morbidity | 16 | 886 | 1704 | 0.05 | 41% | F | OR = 0.88 | 0.70, 1.10 | 0.25 |
| POPF | 17 | 954 | 7629 | 0.42 | 3% | F | OR = 0.95 | 0.79, 1.15 | 0.62 |
| POPF (grade B/C) | 18 | 942 | 1821 | 0.47 | 0 | F | OR = 0.96 | 0.76, 1.22 | 0.75 |
| DGE | 13 | 890 | 7452 | 0.98 | 0 | F | OR = 0.99 | 0.78, 1.24 | 0.90 |
| DGE (grade B/C) | 7 | 479 | 994 | 0.60 | 0 | F | OR = 0.63 | 0.45, 0.88 | 0.006 |
| PPH | 13 | 771 | 7363 | 0.74 | 0 | F | OR = 1.12 | 0.89, 1.42 | 0.34 |
| PPH (grade B/C) | 7 | 454 | 966 | 0.91 | 0 | F | OR = 1.02 | 0.65, 1.60 | 0.95 |
| Bile leak | 8 | 289 | 522 | 0.96 | 0 | F | OR = 1.11 | 0.57, 2.16 | 0.76 |
| Gastroente-ric anastomosis fistula | 4 | 201 | 423 | 0.77 | 0 | F | OR = 0.62 | 0.16, 2.40 | 0.49 |
| Wound infection | 10 | 612 | 7033 | 0.38 | 7% | F | OR = 0.48 | 0.34, 0.67 | < 0.0001 |
| Intra-abdominal abscess | 6 | 455 | 6676 | 0.32 | 14% | F | OR = 0.97 | 0.71, 1.31 | 0.82 |
| Bowel obstruction | 2 | 73 | 73 | 0.33 | 0 | F | OR = 1.00 | 0.14, 7.31 | 1.00 |
| Fluid collection | 3 | 142 | 367 | 0.20 | 37% | F | OR = 1.50 | 0.90, 2.48 | 0.12 |
| Pneumonia | 13 | 1489 | 22399 | 0.99 | 0 | F | OR = 0.72 | 0.60, 0.85 | 0.0002 |
| Cardiac event | 6 | 1200 | 21877 | 0.75 | 0 | F | OR = 1.04 | 0.82, 1.32 | 0.75 |
| Reoperation | 14 | 881 | 7616 | 0.40 | 5% | F | OR = 1.10 | 0.83, 1.47 | 0.51 |
| ICU admission | 2 | 171 | 283 | 0.40 | 0 | F | OR = 0.90 | 0.53, 1.54 | 0.71 |
| ICU stay | 2 | 65 | 227 | 0.62 | 0 | F | WMD = -2.08 | -2.88, -1.29 | < 0.00001 |
| Diet Start Time | 3 | 175 | 284 | <0.0001 | 90% | R | WMD = -1.75 | -3.38, -0.12 | 0.04 |
| LOS | 10 | 1544 | 11922 | < 0.00001 | 78% | R | WMD = -3.05 | -3.93, -2.17 | < 0.00001 |
| Discharge to a new facility | 4 | 498 | 6826 | 0.74 | 0 | F | OR = 0.55 | 0.39, 0.78 | 0.0008 |
| 30-d readmission | 10 | 2006 | 19786 | 0.30 | 15% | F | OR = 0.81 | 0.68, 0.95 | 0.010 |
| 90-d readmission | 4 | 136 | 279 | 0.70 | 0 | F | OR = 1.07 | 0.62, 1.84 | 0.81 |
| 30-d mortality | 18 | 2870 | 35337 | 0.70 | 0 | F | OR = 1.00 | 0.81, 1.24 | 1.00 |
| 90-d mortality | 11 | 1273 | 9159 | 0.77 | 0 | F | OR = 0.77 | 0.58, 1.01 | 0.06 |
EBL: Estimated blood loss; Major morbidity: Clavien-Dindo classification ≥ III; POPF: Postoperative pancreatic fistula; DGE: Delayed gastric emptying; PPH: Postpancreatectomy hemorrhage; LOS: Length of hospital stay; ICU: Intensive care unit; WMD: Weighted mean difference; OR: Odds ratio; CI: Confidence interval; F: Fixed-effects model; R: Random-effects model; TLPD: Total laparoscopic pancreaticoduodenectomy; OPD: Open pancreaticoduodenectomy.
Results of sensitivity analysis of total laparoscopic pancreaticoduodenectomy vs open pancreaticoduodenectomy
| Operative time | 10 | 577 | 1064 | < 0.00001 | 98% | R | WMD = 74.66 | 43.71, 105.62 | < 0.00001 |
| EBL | 9 | 547 | 1034 | < 0.00001 | 95% | R | WMD = -280.46 | -347.73, -213.19 | < 0.00001 |
| Transfusion rate | 10 | 573 | 1071 | 0.15 | 32% | F | OR = 0.45 | 0.35, 0.58 | < 0.00001 |
| Overall morbidity | 9 | 381 | 607 | 0.31 | 15% | F | OR = 0.88 | 0.65, 1.18 | 0.38 |
| Major morbidity | 15 | 829 | 1414 | 0.49 | 0 | F | OR = 0.75 | 0.59, 0.96 | 0.02 |
| POPF | 15 | 617 | 1003 | 0.61 | 0 | F | OR = 0.82 | 0.64, 1.05 | 0.11 |
| POPF (grade B/C) | 17 | 877 | 1531 | 0.89 | 0 | F | OR = 0.86 | 0.66, 1.11 | 0.24 |
| DGE | 10 | 523 | 801 | 0.93 | 0 | F | OR = 0.93 | 0.64, 1.34 | 0.69 |
| DGE (grade B/C) | 7 | 479 | 994 | 0.60 | 0 | F | OR = 0.63 | 0.45, 0.88 | 0.006 |
| PPH | 11 | 434 | 737 | 0.84 | 0 | F | OR = 1.48 | 0.93, 2.36 | 0.10 |
| PPH (grade B/C) | 7 | 454 | 966 | 0.91 | 0 | F | OR = 1.02 | 0.65, 1.60 | 0.95 |
| Bile leak | 7 | 232 | 232 | 0.93 | 0 | F | OR = 1.00 | 0.45, 2.25 | 0.99 |
| Gastroente-ric anastomosis fistula | 3 | 136 | 133 | 0.54 | 0 | F | OR = 0.49 | 0.09, 2.73 | 0.42 |
| Wound infection | 9 | 332 | 697 | 0.46 | 0 | F | OR = 0.57 | 0.39, 0.84 | 0.005 |
| Intra-abdominal abscess | 5 | 175 | 340 | 0.23 | 29% | F | OR = 0.74 | 0.39, 1.38 | 0.34 |
| Bowel obstruction | 2 | 73 | 73 | 0.33 | 0 | F | OR = 1.00 | 0.14, 7.31 | 1.00 |
| Fluid collection | 2 | 77 | 77 | 0.96 | 0 | F | OR = 0.63 | 0.21, 1.89 | 0.41 |
| Pneumonia | 10 | 463 | 880 | 0.99 | 0 | F | OR = 0.79 | 0.54, 1.15 | 0.21 |
| Cardiac event | 4 | 239 | 648 | 0.48 | 0 | F | OR = 1.11 | 0.75, 1.62 | 0.61 |
| Reoperation | 12 | 544 | 990 | 0.46 | 0 | F | OR = 0.76 | 0.48, 1.21 | 0.25 |
| ICU admission | 2 | 171 | 283 | 0.40 | 0 | F | OR = 0.90 | 0.53, 1.54 | 0.71 |
| ICU stay | 2 | 65 | 227 | 0.62 | 0 | F | WMD = -2.08 | -2.88, -1.29 | < 0.00001 |
| Diet start time | 3 | 175 | 284 | <0.0001 | 90% | R | WMD = -1.75 | -3.38, -0.12 | 0.04 |
| LOS | 8 | 332 | 500 | 0.004 | 67% | R | WMD = -3.69 | -4.90, -2.48 | < 0.00001 |
| Discharge to a new facility | 3 | 218 | 490 | 0.60 | 0 | F | OR = 0.50 | 0.28, 0.87 | 0.01 |
| 30-d readmission | 6 | 340 | 508 | 0.77 | 0 | F | OR = 1.04 | 0.68, 1.59 | 0.86 |
| 90-d readmission | 4 | 136 | 279 | 0.70 | 0 | F | OR = 1.07 | 0.62, 1.84 | 0.81 |
| 30-d mortality | 12 | 527 | 1271 | 0.76 | 0 | F | OR = 1.26 | 0.59, 2.68 | 0.55 |
| 90-d mortality | 9 | 312 | 661 | 0.96 | 0 | F | OR = 0.60 | 0.31, 1.17 | 0.14 |
| Time to adjuvant chemothe-rapy | 1 | 39 | 141 | NA | NA | F | WMD = -5.50 | -12.71, 1.71 | 0.14 |
| Tumor size | 9 | 430 | 745 | 0.0002 | 73% | R | WMD = -0.36 | -0.63, -0.09 | 0.008 |
| RLNs | 10 | 388 | 925 | < 0.00001 | 79% | R | WMD = 1.28 | 0.29, 2.27 | 0.01 |
| R0 rate | 16 | 605 | 1535 | 0.87 | 0 | F | OR = 1.44 | 1.07, 1.94 | 0.02 |
| OS of PDAC | |||||||||
| 1-yr OS | 2 | 65 | 427 | 0.49 | 0 | F | OR = 0.65 | 0.37, 1.13 | 0.12 |
| 2-yr OS | 2 | 65 | 427 | 0.74 | 0 | F | OR = 0.54 | 0.27, 1.07 | 0.08 |
| 3-yr OS | 2 | 65 | 427 | 0.37 | 0 | F | OR = 0.98 | 0.46, 2.10 | 0.96 |
| 4-yr OS | 2 | 65 | 427 | 0.82 | 0 | F | OR = 1.04 | 0.43, 2.52 | 0.93 |
| 5-yr OS | 2 | 65 | 427 | 0.27 | 17% | F | OR = 0.65 | 0.19, 2.23 | 0.49 |
| OS of periampullary adenocarcinoma patients | |||||||||
| 1-yr OS | 2 | 23 | 234 | 0.004 | 88% | R | OR = 0.85 | 0.01, 107.31 | 0.95 |
| 3-yr OS | 2 | 23 | 234 | 0.01 | 84% | R | OR = 0.90 | 0.01, 86.00 | 0.96 |
| 5-yr OS | 2 | 23 | 234 | 0.26 | 20% | F | OR = 1.57 | 0.43, 5.73 | 0.49 |
NA: Not applicable; EBL: Estimated blood loss; Major morbidity: Clavien-Dindo classification ≥ III; RLNs: Retrieved lymph nodes; POPF: Postoperative pancreatic fistula; DGE: Delayed gastric emptying; PPH: Postpancreatectomy hemorrhage; LOS: Length of hospital stay; ICU: Intensive care unit; RFS: Recurrence-free survival; OS: Overall survival; PDAC: Pancreatic ductal adenocarcinoma; WMD: Weighted mean difference; OR: Odds ratio; CI: Confidence interval; F: Fixed-effects model; R: Random-effects model; TLPD: Total laparoscopic pancreaticoduodenectomy; OPD: Open pancreaticoduodenectomy.
Figure 2Forest plots of the meta-analysis. A: Operative time; B: Estimated blood loss; C: Transfusion rate; D: Overall morbidity; E: Postoperative pancreatic fistula; F: Delayed gastric emptying; G: Delayed gastric emptying (grade B/C); H: Bile leak; I: Postpancreatectomy hemorrhage; J: Wound infection; K: Pneumonia; L: Duration of intensive care unit stay; M: Length of hospital stay; N: Discharge to a new facility; O: 30-d readmission; P: Tumor size; Q: Retrieved lymph nodes; R: R0 resection; S: Time to adjuvant chemotherapy.
Meta-analysis of oncological outcomes
| Tumor size | 10 | 814 | 4782 | < 0.00001 | 85% | R | WMD = -0.32 | -0.58, -0.07 | 0.01 |
| RLNs | 12 | 1600 | 12347 | < 0.00001 | 77% | R | WMD = 1.32 | 0.57, 2.06 | 0.0005 |
| R0 rate | 19 | 1991 | 14477 | 0.88 | 0 | F | OR = 1.28 | 1.13, 1.44 | 0.0001 |
| Time to adjuvant chemotherapy | 2 | 867 | 7526 | 0.39 | 0 | F | WMD = -2.44 | -4.39, -0.49 | 0.01 |
| 1-yr RFS | 2 | 52 | 37 | NA | NA | F | OR = 0.44 | 0.16, 1.23 | 0.12 |
| 3-yr RFS | 2 | 52 | 37 | 0.22 | 35% | F | OR = 0.53 | 0.19, 1.47 | 0.22 |
| 5-yr RFS | 2 | 52 | 37 | 0.31 | 4% | F | OR = 0.40 | 0.12, 1.33 | 0.14 |
| 1-yr OS | 5 | 412 | 2206 | 0.007 | 72% | R | OR = 0.62 | 0.33, 1.19 | 0.15 |
| 2-yr OS | 4 | 400 | 2194 | 0.03 | 66% | R | OR = 0.61 | 0.32, 1.17 | 0.14 |
| 3-yr OS | 5 | 412 | 2206 | 0.08 | 51% | R | OR = 0.80 | 0.40, 1.62 | 0.54 |
| 4-yr OS | 4 | 400 | 2194 | 0.60 | 0 | F | OR = 0.73 | 0.41, 1.30 | 0.28 |
| 5-yr OS | 6 | 520 | 2420 | 0.52 | 0 | F | OR = 0.78 | 0.38, 1.59 | 0.49 |
| 1-yr OS | 3 | 349 | 1947 | 0.28 | 22% | F | OR = 0.93 | 0.74, 1.18 | 0.57 |
| 2-yr OS | 3 | 349 | 1947 | 0.21 | 37% | F | OR = 0.93 | 0.70, 1.24 | 0.63 |
| 3-yr OS | 3 | 349 | 1947 | 0.60 | 0 | F | OR = 0.86 | 0.56, 1.34 | 0.52 |
| 4-yr OS | 3 | 349 | 1947 | 0.95 | 0 | F | OR = 0.97 | 0.49, 1.92 | 0.94 |
| 5-yr OS | 3 | 349 | 1947 | 0.27 | 17% | F | OR = 0.65 | 0.19, 2.23 | 0.49 |
| 1-yr OS | 3 | 349 | 1947 | 0.28 | 22% | F | OR = 0.93 | 0.74, 1.18 | 0.57 |
| 2-yr OS | 3 | 349 | 1947 | 0.21 | 37% | F | OR = 0.93 | 0.70, 1.24 | 0.63 |
| 3-yr OS | 3 | 349 | 1947 | 0.60 | 0 | F | OR = 0.86 | 0.56, 1.34 | 0.52 |
| 4-yr OS | 3 | 349 | 1947 | 0.95 | 0 | F | OR = 0.97 | 0.49, 1.92 | 0.94 |
| 5-yr OS | 3 | 349 | 1947 | 0.27 | 17% | F | OR = 0.65 | 0.19, 2.23 | 0.49 |
| 5-yr OS | 6 | 520 | 2420 | 0.52 | 0 | F | OR = 0.78 | 0.38, 1.59 | 0.49 |
RLNs: Retrieved lymph nodes; RFS: Recurrence-free survival; OS: Overall survival; PDAC: Pancreatic ductal adenocarcinoma; OR: Odds Ratio; CI: Confidence interval; F: Fixed-effects model; R: Random-effects model; NA: Not applicable; TLPD: Total laparoscopic pancreaticoduodenectomy; OPD: Open pancreaticoduodenectomy.